CARGO THERAPEUTICS INC (CRGX)
US14179K1016 - Common Stock
CRGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRGX as it has an excellent financial health rating, but there are worries on the profitability. CRGX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CRGX has reported negative net income.
In the past year CRGX has reported a negative cash flow from operations.
1.2 Ratios
The Return On Assets of CRGX (-34.18%) is better than 63.70% of its industry peers.
CRGX has a better Return On Equity (-38.45%) than 73.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.18% | ||
| ROE | -38.45% | ||
| ROIC | N/A |
ROA(3y)-183.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRGX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CRGX has an Altman-Z score of 7.15. This indicates that CRGX is financially healthy and has little risk of bankruptcy at the moment.
CRGX has a better Altman-Z score (7.15) than 84.16% of its industry peers.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.15 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 18.95 indicates that CRGX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 18.95, CRGX belongs to the top of the industry, outperforming 94.31% of the companies in the same industry.
CRGX has a Quick Ratio of 18.95. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 18.95, CRGX belongs to the top of the industry, outperforming 94.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.95 | ||
| Quick Ratio | 18.95 |
3. Growth
3.1 Past
CRGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -124.71%.
EPS 1Y (TTM)-124.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, CRGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.13% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.22%
EPS Next 2Y34.81%
EPS Next 3Y22.17%
EPS Next 5Y14.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CRGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CRGX's earnings are expected to grow with 22.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.81%
EPS Next 3Y22.17%
5. Dividend
5.1 Amount
No dividends for CRGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARGO THERAPEUTICS INC
NASDAQ:CRGX (12/27/2024, 10:44:49 AM)
13.985
-0.91 (-6.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.97%
Inst Owner Change7.49%
Ins Owners0.24%
Ins Owner Change0%
Market Cap643.73M
Analysts84
Price Target32.49 (132.32%)
Short Float %14.08%
Short Ratio27.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.19%
Min EPS beat(2)2.64%
Max EPS beat(2)23.75%
EPS beat(4)3
Avg EPS beat(4)11.05%
Min EPS beat(4)-1.21%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.18%
PT rev (3m)0.18%
EPS NQ rev (1m)12.28%
EPS NQ rev (3m)34.58%
EPS NY rev (1m)11.62%
EPS NY rev (3m)11.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.61 | ||
| P/tB | 1.61 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.26
EYN/A
EPS(NY)-4.19
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-2.91
OCFYN/A
SpS0
BVpS8.71
TBVpS8.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.18% | ||
| ROE | -38.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-183.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 267.3% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.95 | ||
| Quick Ratio | 18.95 | ||
| Altman-Z | 7.15 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1145.04%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-124.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.14%
EPS Next Y83.22%
EPS Next 2Y34.81%
EPS Next 3Y22.17%
EPS Next 5Y14.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-178.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.78%
EBIT Next 3Y-38.2%
EBIT Next 5YN/A
FCF growth 1Y-181.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-179.2%
OCF growth 3YN/A
OCF growth 5YN/A